99 related articles for article (PubMed ID: 7753547)
61. Restoration of wild-type conformation to full-length and truncated p53 proteins: specific effects of ATP and ADP.
Warnock LJ; Raines SA
Cancer Biol Ther; 2004 Jul; 3(7):634-7. PubMed ID: 15136763
[TBL] [Abstract][Full Text] [Related]
62. Divalent metal ions induce conformational change in pure, human wild-type p53 tumor suppressor protein.
Coffer AI; Knowles PP
Biochim Biophys Acta; 1994 Dec; 1209(2):279-85. PubMed ID: 7811703
[TBL] [Abstract][Full Text] [Related]
63. Clinical implications of p53 alterations in oral cancer progression: a review from India.
Patel KR; Vajaria BN; Singh RD; Begum R; Patel PS
Exp Oncol; 2018 Mar; 40(1):10-18. PubMed ID: 29600984
[TBL] [Abstract][Full Text] [Related]
64. Hydrophobicity at the surface of proteins.
Scarsi M; Majeux N; Caflisch A
Proteins; 1999 Dec; 37(4):565-75. PubMed ID: 10651272
[TBL] [Abstract][Full Text] [Related]
65. The Basally Expressed p53-Mediated Homeostatic Function.
Nagpal I; Yuan ZM
Front Cell Dev Biol; 2021; 9():775312. PubMed ID: 34888311
[TBL] [Abstract][Full Text] [Related]
66. How Do Cancer-Related Mutations Affect the Oligomerisation State of the p53 Tetramerisation Domain?
Nicolini F; Todorovski T; Puig E; Díaz-Lobo M; Vilaseca M; García J; Andreu D; Giralt E
Curr Issues Mol Biol; 2023 Jun; 45(6):4985-5004. PubMed ID: 37367066
[TBL] [Abstract][Full Text] [Related]
67. Confocal Spectroscopy to Study Dimerization, Oligomerization and Aggregation of Proteins: A Practical Guide.
Gambin Y; Polinkovsky M; Francois B; Giles N; Bhumkar A; Sierecki E
Int J Mol Sci; 2016 Apr; 17(5):. PubMed ID: 27144560
[TBL] [Abstract][Full Text] [Related]
68. Nucleolar protein GLTSCR2 stabilizes p53 in response to ribosomal stresses.
Lee S; Kim JY; Kim YJ; Seok KO; Kim JH; Chang YJ; Kang HY; Park JH
Cell Death Differ; 2012 Oct; 19(10):1613-22. PubMed ID: 22522597
[TBL] [Abstract][Full Text] [Related]
69. The p53 isoforms are differentially modified by Mdm2.
Camus S; Ménendez S; Fernandes K; Kua N; Liu G; Xirodimas DP; Lane DP; Bourdon JC
Cell Cycle; 2012 Apr; 11(8):1646-55. PubMed ID: 22487680
[TBL] [Abstract][Full Text] [Related]
70. Resistance of mitochondrial p53 to dominant inhibition.
Heyne K; Schmitt K; Mueller D; Armbruester V; Mestres P; Roemer K
Mol Cancer; 2008 Jun; 7():54. PubMed ID: 18547443
[TBL] [Abstract][Full Text] [Related]
71. Ubiquitination and degradation of mutant p53.
Lukashchuk N; Vousden KH
Mol Cell Biol; 2007 Dec; 27(23):8284-95. PubMed ID: 17908790
[TBL] [Abstract][Full Text] [Related]
72. Destabilizing missense mutations in the tumour suppressor protein p53 enhance its ubiquitination in vitro and in vivo.
Shimizu H; Saliba D; Wallace M; Finlan L; Langridge-Smith PR; Hupp TR
Biochem J; 2006 Jul; 397(2):355-67. PubMed ID: 16579792
[TBL] [Abstract][Full Text] [Related]
73. Regulation of tumor angiogenesis by p53-induced degradation of hypoxia-inducible factor 1alpha.
Ravi R; Mookerjee B; Bhujwalla ZM; Sutter CH; Artemov D; Zeng Q; Dillehay LE; Madan A; Semenza GL; Bedi A
Genes Dev; 2000 Jan; 14(1):34-44. PubMed ID: 10640274
[TBL] [Abstract][Full Text] [Related]
74. Mdm2: the ups and downs.
Juven-Gershon T; Oren M
Mol Med; 1999 Feb; 5(2):71-83. PubMed ID: 10203572
[No Abstract] [Full Text] [Related]
75. DNA damage-inducible phosphorylation of p53 at N-terminal sites including a novel site, Ser20, requires tetramerization.
Shieh SY; Taya Y; Prives C
EMBO J; 1999 Apr; 18(7):1815-23. PubMed ID: 10202145
[TBL] [Abstract][Full Text] [Related]
76. Regulation of p53 function and stability by phosphorylation.
Ashcroft M; Kubbutat MH; Vousden KH
Mol Cell Biol; 1999 Mar; 19(3):1751-8. PubMed ID: 10022862
[TBL] [Abstract][Full Text] [Related]
77. Regulation of Mdm2-directed degradation by the C terminus of p53.
Kubbutat MH; Ludwig RL; Ashcroft M; Vousden KH
Mol Cell Biol; 1998 Oct; 18(10):5690-8. PubMed ID: 9742086
[TBL] [Abstract][Full Text] [Related]
78. Proteolytic cleavage of human p53 by calpain: a potential regulator of protein stability.
Kubbutat MH; Vousden KH
Mol Cell Biol; 1997 Jan; 17(1):460-8. PubMed ID: 8972227
[TBL] [Abstract][Full Text] [Related]
79. Oligomerisation of full length p53 contributes to the interaction with mdm2 but not HPV E6.
Marston NJ; Jenkins JR; Vousden KH
Oncogene; 1995 May; 10(9):1709-15. PubMed ID: 7753547
[TBL] [Abstract][Full Text] [Related]
80. Hypoxia induces p53 accumulation through MDM2 down-regulation and inhibition of E6-mediated degradation.
Alarcón R; Koumenis C; Geyer RK; Maki CG; Giaccia AJ
Cancer Res; 1999 Dec; 59(24):6046-51. PubMed ID: 10626788
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
